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GREENAWAY, JR., Circuit Judge.
The discharge of claims in bankruptcy applies with no less force to claims that are 
meritorious, sympathetic, or diligently pursued.  Though the result may chafe one’s 
innate sense of fairness, not all unfairness represents a violation of due process.  
 John Sweeney’s symptoms first manifested in 2009.  In 2014, he was diagnosed 
with adhesive arachnoiditis.  It was not until 2015 that he identified a likely source of his 
injuries: his 1975 exposure to a product called Pantopaque, whose harmful ingredient 
(iophendylate) Kodak allegedly had manufactured.   
 By the time Mr. Sweeney ascertained this alleged causal connection, Kodak had 
undergone reorganization pursuant to chapter 11 of the Bankruptcy Code.  As part of this 
 
*  This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does 




process, prepetition claims against Kodak (such as those brought by Mr. Sweeney and 
Regina Sweeney, his wife) had been discharged.   
 The Sweeneys assert that the discharge of their claims was not effective because 
Kodak had not complied with the dictates of due process.  They argue that Kodak’s 
notice of the deadline for filing proofs of claim (the “claims bar date”) should have 
included language announcing that persons injured as a result of Pantopaque exposure 
might have claims against Kodak.  However, based on the facts pleaded in the Fifth 
Amended Complaint, requiring such language here would work a dramatic expansion of 
a bankruptcy debtor’s onus with respect to providing notice to unknown creditors.   
The District Court correctly found that Kodak provided sufficient notice to satisfy 
due process.  We will affirm.1  
I. Background2  
In 1975, fifteen-year-old Mr. Sweeney sustained significant injuries while playing 
football.   During his treatment, physicians injected Pantopaque, a medical-imaging dye 
product, into his spinal canal.  Kodak manufactured iophendylate, a chemical component 
of Pantopaque.  
Articles in medical journals had warned as early as 1945 that dyes used in 
Pantopaque were linked to a severely debilitating condition known as adhesive 
 
1  The District Court had jurisdiction pursuant to 28 U.S.C. § 1332.  This Court has 
jurisdiction pursuant to 28 U.S.C. §§ 158(d)(1) and 1291(3).   
2  Because the District Court dismissed the Sweeneys’ claims pursuant to Federal 
Rule of Civil Procedure 12(b)(6), we accept the facts pleaded in the Fifth Amended 
Complaint as true.  We consider only the facts pleaded in the operative complaint or 




arachnoiditis, and in 1969 the FDA requested that Pantopaque’s distributor add specific 
cautionary language to that effect to its products.  Yet the warning label used on 
Pantopaque in 1975 did not include such language and instead minimized the product’s 
risks (though it did contain the phrase “severe arachnoiditis”).   
As of September 1976, Mr. Sweeney enjoyed a full recovery from his football 
injuries, but beginning in 2009, he began to experience increasing lower extremity 
weakness, numbness, clumsiness, and difficulty walking, resulting in increased falls.  By 
2013, he had been forced to relocate his bed to the lower floor of his home.  He submitted 
to medical testing beginning in 2009 and was diagnosed with advanced adhesive 
arachnoiditis in August 2014.  This prompted him to search for the cause of his 
arachnoiditis, and an internet search revealed a possible causal link to his exposure to 
Pantopaque decades earlier.  In late 2015, by which time Mr. Sweeney had been 
diagnosed with end-stage adhesive arachnoiditis, a neurosurgeon confirmed that his 
exposure to Pantopaque had likely caused his progressive loss of lower extremity 
function.   
In 2012, before Mr. Sweeney had received a diagnosis, Kodak filed a voluntary 
petition with the Bankruptcy Court of the Southern District of New York (the 
“Bankruptcy Court”) under chapter 11 of Title 11 of the United States Code.  Pursuant to 
the Bankruptcy Court’s directives, Kodak first published notice of the deadline for filing 
proofs of claim in the National Edition of The New York Times and in the Democrat and 




confirmation hearing in USA Today; The Wall Street Journal, National Edition; and the 
Democrat and Chronicle.   
On August 23, 2013, the Bankruptcy Court confirmed Kodak’s plan of 
reorganization (the “Bankruptcy Plan”).  The Bankruptcy Plan discharged and terminated 
all claims against Kodak, known or unknown, and enjoined the commencement or 
prosecution of any claims or causes of action so discharged.  The Bankruptcy Court’s 
Confirmation Order contained a similar injunction.   
The Sweeneys commenced this personal injury lawsuit against Kodak and its co-
defendants (which are not party to this appeal) in 2016.  In 2018, Kodak moved to 
dismiss the claims against it pursuant to Sections 524 and 1141(d)(1) of the Bankruptcy 
Code; the Bankruptcy Court’s August 23, 2013 order confirming Kodak’s Bankruptcy 
Plan; and “the [District] Court’s inherent judicial powers.”  App. 34a.  The District Court 
treated the motion as a motion to dismiss pursuant to Federal Rule of Civil Procedure 
12(b)(6).   
 The District Court granted the motion to dismiss the claims against Kodak, 
holding that “under either Second or Third Circuit law, Plaintiffs[’] claims must be 
dismissed because, for unknown creditors, notice by publication was sufficient to satisfy 
due process.”  Sweeney v. Lafayette Pharm., Inc., 2020 WL 2079283, at *2 (D.N.J. Apr. 
30, 2020).  The District Court found that the factors set forth by this Court in dicta in 
Jeld-Wen, Inc. v. Van Brunt (In re Grossman’s Inc.), 607 F.3d 114, 127–28 (3d Cir. 
2010) (en banc), bolstered the case for discharge.  In assessing these factors, it noted that 




at the motion to dismiss stage”; while it “acknowledge[d] that discovery could allow it to 
do a more fulsome analysis,” it found that the record was sufficient for it to decide the 
issue.  Sweeney, 2020 WL 2079283, at *5 n.6.   
II. Discussion3 
Section 1141(d)(1)(A) of the Bankruptcy Code provides that the confirmation of a 
reorganization plan “discharges the debtor from any debt that arose before the date of 
such confirmation,” notwithstanding whether “the holder of such claim has accepted the 
plan.”  11 U.S.C. § 1141(d)(1)(A).  Pursuant to 11 U.S.C. § 524(a)(2), a discharge 
“operates as an injunction against the commencement or continuation of an action, the 
employment of process, or an act, to collect, recover or offset any such debt as a personal 
liability of the debtor, whether or not discharge of such debt is waived.”  These 
provisions were echoed in the Plan and Confirmation Order at issue here.     
Because the parties agreed that Appellants’ claims against Kodak were prepetition 
claims, due process is the dispositive issue; the Bankruptcy Court’s Confirmation Order 
would have operated to discharge the Sweeneys’ claims unless the notice of the claims 
bar date and bankruptcy confirmation hearing provided by Kodak failed to afford the 
Sweeneys due process.  Sweeney, 2020 WL 2079283, at *2; see In re Grossman’s Inc., 
607 F.3d at 125–26 (claims otherwise subject to discharge are not discharged where 
“fundamental principles of due process” have not been satisfied).   
 
3  We exercise plenary review of the District Court’s grant of the motion to dismiss.  
See In re Schering Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235, 




Appellants concede that the manner of notice—publication in papers of national 
circulation and one local periodical—was constitutionally sufficient.  Yet they argue that 
due process was not satisfied because the content of the notice omitted critical 
information.  While the case law in this area tends to focus on the manner of notice, 
generally content is a critical component of due process.  See Mullane v. Cent. Hanover 
Bank & Tr. Co., 339 U.S. 306, 314 (1950) (“The notice must be of such nature as 
reasonably to convey the required information.”4 (emphasis added)).   
With respect to manner and content both, reasonableness is the touchstone of the 
due process analysis.  Thus, the Supreme Court has endorsed “resort to publication as a 
customary substitute . . . where it is not reasonably possible or practicable to give more 
adequate warning,” as “in the case of persons missing or unknown.”5  Id. at 317.  In the 
same vein, persons who cannot be identified or located without travail may be deemed 
“missing or unknown”: “impracticable and extended searches are not required in the 
name of due process.”  Id. at 317–18.   
In this Circuit, reasonable diligence on the part of a debtor requires a 
“search . . . focuse[d] on the debtor’s own books and records,” and a “careful 
examination of [those] documents.”  Chemetron Corp. v. Jones, 72 F.3d 341, 347 (3d Cir. 
 
4  The Court also observed that notice by publication is especially unlikely to be 
effectual where it “does not even name those whose attention it is supposed to attract, and 
does not inform acquaintances who might call it to attention.”  Mullane, 339 U.S. at 315. 
5  In Mullane, the claims were unknown to the debtor.  We have suggested that 
publication notice might not be enough if the claims were unknown even to the creditor 
herself during the bankruptcy.  See Wright v. Owens Corning, 679 F.3d 101, 108 n.7 (3d 




1995).  A debtor need not conduct a “vast, open-ended investigation,” nor must it “search 
out each conceivable or possible creditor and urge that person or entity to make a claim 
against it.”  Id. at 346 (quoting In re Charter Co., 125 B.R. 650, 654 (M.D. Fla. 1991)).  
In Chemetron, we held that because the claimants were “‘unknown’ creditors,” “notice by 
publication was sufficient to satisfy the requirements of due process,” and their claims 
were barred.  Id. at 345–46.  We have since reiterated that “claimants who were unknown 
at the time of the discharge” are “entitled only to publication notice of a property 
deprivation.”  In re Energy Future Holdings Corp, 949 F.3d 806, 822 (3d Cir. 2020).   
There is no bright-line rule that the publication of purported notice, irrespective of 
its content, will discharge all prepetition claims held by unknown persons.  Rather, as we 
stated in Grossman’s, “[w]hether a particular claim has been discharged by a plan of 
reorganization depends on factors applicable to the particular case and is best determined 
by the appropriate bankruptcy court or the district court.”6  607 F.3d at 127.  It may be 
that if a debtor’s records revealed the existence—but not the identities—of persons with 
claims against the debtor, due process would require that the nature of those claims be 
announced in the relevant notices.7  We need not decide as much today, however, 
 
6  In Grossman’s, we enumerated a non-exhaustive set of factors that district courts 
“may wish to consider.”  607 F.3d at 127–28.  Appellants assert the District Court applied 
these factors incorrectly, but this argument presumes that our list was prescriptive.  It was 
not; the considerations were offered only in dicta, and the Court’s diction (“may wish to 
consider” and “inter alia”) underscores that we did not intend to impose a rigid test.  Id. at 
127.   
7  Such circumstances might also warrant the creation of a trust and/or the 
appointment of a future claims representative.  We do not address the propriety of such 
measures in this case, as Appellants have forfeited any argument that they ought to have 




because the Fifth Amended Complaint does not allege that Kodak had actual or 
constructive knowledge of Pantopaque claimholders as of 2012.   
Even when viewed in the light most favorable to Appellants, the Fifth Amended 
Complaint does not support the inference that Kodak, through reasonably diligent efforts, 
should have ascertained the existence of Pantopaque claims against it.  In their briefs, 
Appellants point to a series of Pantopaque-related lawsuits filed in the late 1980s and the 
1990s, urging that these suits demonstrate Kodak’s knowledge of its liability.  We may 
take judicial notice of “another court’s opinion to use it as proof that evidence existed to 
put a party on notice of the facts underlying a claim.”  Sands, 502 F.3d at 268.  However, 
none of the opinions Appellants cite speaks to the contents of Kodak’s books and records 
in 2012.8  See Dohra v. Alcon (P.R.), Inc., 1994 WL 71449 (N.D. Ill. March 3, 1994); 
Staub v. Eastman Kodak Co., 726 A.2d 955 (N.J. Super. Ct. App. Div. 1999); Ahearn v. 
Lafayette Pharmacal, Inc., 729 S.W.2d 501 (Mo. Ct. App. 1987).  Nor is the mere 
existence of the cases sufficient to put Kodak on notice.  The search a bankruptcy debtor 
must undertake is not “open-ended,” but rather “focuses on the debtor’s own books and 
records.”  Chemetron, 72 F.3d at 346–47.   
There is no allegation that previous Pantopaque suits appeared in Kodak’s books 
and records more than a decade after those actions were resolved.  In the absence of 
allegations tending to show that Kodak’s records in 2012 disclosed outstanding 
 
8  In addition to the opinions directly cited, Appellants seek to rely on a chart 
submitted in support of Kodak’s motion to dismiss.  This chart (which is not properly 




Pantopaque claims, we must conclude that the notice provided here was constitutionally 
sufficient.9  To hold otherwise would dramatically expand the burdens borne by debtors.  
See Chemetron, 72 F.3d at 346–47. 
III. Conclusion 
The published notice satisfied the standards of due process here.  We will affirm 
the decision of the District Court.10   
 
9  Judge Bibas would affirm because the Sweeneys’ only objection to the notice is 
that it did not mention Kodak’s connection to Pantopaque.  That detail could not have 
helped Mr. Sweeney or anyone like him.  Once a creditor learns he has been injured by 
Pantopaque, it would be easy for him to find out that Kodak made the active ingredient.  
Sweeney himself made the connection instantly.  The creditor’s problem is that he might 
not yet be injured by the time of the bankruptcy.  Mentioning Kodak’s connection to the 
drug would not solve that problem.  So the detail was not required by due process. 
10  Because we will affirm the District Court’s ruling, we do not reach the question 
whether the Bankruptcy Court for the Southern District of New York would have had 
jurisdiction concurrent with that of the District of New Jersey in this matter.   
